PAM2L Biotechnologies

PAM2L Biotechnologies (柏垠生物) is a synthetic biology company developing bio-based materials, co-founded by chief scientist Professor Zhong Chao and co-founder Cui Junfeng . The company operates a dual-engine technology platform combining synthetic biology and machine learning (BT-IT), with a pipeline focused on protein and polysaccharide innovation for applications in pharmaceuticals, medical aesthetics, cosmetics, and food . In January 2023, it closed a Pre-A round of over 100 million yuan co-led by Yunqi Capital, Woyong Fund, and Fuhua Capital . As 暗涌Waves reported, Zhong described the transition from academia to entrepreneurship as a shift from advisor-directed research to fully market-driven decision-making . By April 2026, Yunqi Capital highlighted that PAM2L's founding team had published breakthrough work in *Nature* on cell differentiation programming that pushes the boundaries of bio-manufacturing .